|
|
|
|
|
|
by tjpnz
12 days ago
|
|
|
>Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working. It's not a cure or the trial has been running <1 year? |
|
|